Atrial fibrosis serves as an important contributor to atrial fibrillation (AF). Recent data have suggested that microRNA-30c (miR-30c) is involved in fibrotic remodelling and cancer development, but the specific role of miR-30c in atrial fibrosis remains unclear. The purpose of this study was to investigate the role of miR-30c in atrial fibrosis and its underlying mechanisms through in vivo and in vitro experiments.
| INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it results in significant morbidity and mortality. 1 Atrial fibrosis plays a key role in the development and maintenance of AF. 2, 3 MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in regulating gene expression, resulting in either translation repression or mRNA degradation through actions on the 3 0 untranslated region (3 0 UTR) of target genes. 4 MiRNAs participate in the pathogenesis of different pathological events, including cardiac fibrosis. 5 Several members of the miR-30 family are highly expressed in the brain, with the exception of miR-30c, which is abundant in cardiac fibroblasts (CFs) and is involved in ventricular fibrosis. 6, 7 Several studies have demonstrated that miR-30c inhibits ventricular collagen synthesis in pathological left ventricular hypertrophy. 10 suggested that miR-30c suppresses renal fibrosis and improves renal function. Taken together, these data suggest that miR-30c is an anti-fibrotic miRNA mediating organ fibrosis. However, it remains unclear whether miR-30c is involved in atrial fibrosis and through what underlying mechanisms.
Fibrosis is a complex process resulting from activation of select signalling pathways, such as TGF-b1 signalling. 11 TGF-b1 is essential for the development of atrial fibrosis. [12] [13] [14] The levels of TGF-b1 are increased in the plasma and atria of AF patients. 15, 16 Moreover, animal models have revealed that transgenic overexpression of TGF-b1 results in atrial-specific fibrosis and increases AF susceptibility. [17] [18] [19] Thus, we used TGF-b1-induced CFs to establish an in vitro model of atrial fibrosis. TGF-b1 mediates its effects via interactions among transmembrane receptors, including type I (TGFbRI), type II (TGFbRII) and type III (TGFbRIII). Upon binding to TGF-b1, TGFbRII recruits and phosphorylates TGFbRI, which initiates signal transduction via Smad proteins. 20 TGFbRII can transduce the TGF-b1 signalling from cell membrane to the cytoplasm and then regulate a series of physiological or pathological processes including cell proliferation, differentiation 21, 22 and collagen production. 23 We identified TGFbRII as a direct target of miR-30c using a microRNA target prediction tool (RNAhybrid). Recent studies show that TGFbRII is a target gene of several anti-fibrotic miRNAs. Liang et al 24 suggested that miR-153, an anti-fibrotic miRNA, inhibits the migration of pulmonary fibroblasts and reduces pulmonary fibrosis by targeting TGFbRII. As shown in the study by Zou et al 25 , miR-19a-3p/19b-3p inhibits autophagymediated fibrogenesis by targeting TGFbRII. Another study suggested that miR-145 prevents TGFb-dependent ECM accumulation and fibrosis in smooth muscle cells by targeting TGFbRII. 26 Additionally, a recent study showed that constitutive expression of dominant-negative TGFbRII in the posterior left atrium in a canine heart failure model could sufficiently attenuate fibrosis-induced changes in atrial conduction and restitution to decrease AF. 27 Collectively, these data suggested that miR-30c and TGFbRII were critical for TGF-b1-mediated fibrosis. Therefore, we hypothesize that miR-30c represses TGFbRII expression, subsequently decreasing CF proliferation, differentiation, migration and collagen synthesis. Our present work aimed to elucidate the effects of miR30c on atrial fibrosis and TGF-b1-induced fibrosis performed with in vivo and in vitro experimental approaches, and this may provide a potential therapeutic target to prevent atrial fibrosis.
| MATERIALS AND METHODS

| Rat model of atrial fibrosis and Adenovirus
Injection
All animal protocols in this study were approved by the Animal Care Fifteen Sprague-Dawley rats weighing 200-250 grams were randomly divided into sham (n = 7) and AAC (n = 8) groups. [30] [31] [32] Thence, AAV9 expressing miR-30c (AAV9-miR-30c) and a negative control (AAV9-Control) were used to determine whether miR-30c overexpression is sufficient to reduce atrial fibrosis in AAC models. AAV9-miR-30c or AAV9-Control (Hanheng Biotechnology, China) was randomly injected into inferior vena cava (IVC) with insulin needles, as soon as AAC at 1.8 9 10 11 v.g./200 ll per rat. 31 The rats were randomly divided into 4 groups: Sham (n = 6), AAC (n = 8), AAC+ miR-30c (n=8) and AAC+ Control (n=8). After treatment for 8 weeks, excessive anaesthesia, venous thrombosis, resulted in 4 deaths, leaving the number of rats in the 4 groups was Sham (n = 6), AAC (n = 6), AAC + miR-30c (n = 7) and AAC + Control (n = 7). The left atrium was removed and divided into 2 parts.
One part was rapidly frozen in liquid nitrogen for subsequent RNA isolation, protein isolation, and the remaining part was kept in 4%
(w/v) paraformaldehyde (PFA) for histological analysis. Table 1 . The bulge-loop ™ miRNA Primer Sets (one RT primer and a pair of qPCR primers) specific for miR-30c and U6
were purchased from RiboBio (Guangzhou, China). The levels of mRNA and miR-30c were normalized to b-Actin and U6, respectively.
Briefly, the cycle threshold (CT) values of each targeting gene were subtracted from the CT values of the housekeeping gene, referring as
Mct. Target gene MMct was determined as Mct of target gene minus
Mct of control. The relative expression levels of all genes were calculated basing on the 2
ÀDDct
. All samples were assayed in triplicate.
| Cell proliferation
Cell growth was analysed using cell counting kit-8 (CCK-8) solution (Dojindo, Japan) according to the manufacturer's instructions. Briefly, the cells were plated at a density of 5 9 10 3 cells per well in 96-well plates and transfected as described above. Then, the medium in each well was substituted with 10 ll CCK-8 solution for 2 hours.
The absorbance at 450 nm was measured using a multimode reader. 
| Cell migration assays
| Western blot analysis
Briefly, total protein was isolated from ground frozen atrium tissues and CFs using RIPA lysis buffer (Beyotime, China). The samples were clarified by centrifugation at 13 800 g for 15 minutes at 4°C. Protein concentrations were determined using the BCA Protein Assay Kit 
| Dual luciferase activity assay
To investigate the target gene of miR-30c, bioinformatic prediction algorithms were used to analyse and identify potential targets. In T A B L E 1 Nucleotide sequences of the qRT-PCR primers Figure 1A,B) . In addition, we confirmed that miR-30c was down-regulated in atrial samples from AAC model rats via quantitative Real-Time PCR (qRT-PCR) ( Figure 1C) .
Furthermore, the level of miR-30c was also decreased in CFs stimulated with TGF-b1 ( Figure 1F ). Taken together, these data supported a potential role for miR-30c for atrial fibrosis. The TGFbRII expressions were increased both in AAC models and cultured neonatal rat
CFs stimulated with TGF-b1 ( Figure 1D -F).
| miR-30c reduces TGF-b1-induced CF proliferation, differentiation and migration
Next, we investigated the effect of miR-30c on CF proliferation, differentiation migration and ECM-related proteins in vitro. Based on the qRT-PCR analysis, we confirmed that miR-30c was successfully up-regulated after transfected with miR-30c mimic for 72 hours (Figure 2A) . First, we observed that miR-30c mimic significantly inhibited (Figure 2B ). In addition, the overexpressing miR-30c attenuated the differentiation of CFs into myofibroblasts as indicated by decreased the levels of vimentin and a-smooth muscle actin (a-SMA) (Figure 2C-E) , which is a reliable and classic marker for the myofibroblast. [33] [34] [35] Furthermore, our result demonstrated that a miR-30c mimic inhibited CF stimulated with or without TGF-b1 migration via transwell migration assay ( Figure 2F,G) . Similarly, overexpression of miR30c inhibited the increased mRNA and protein levels of collagen I (Col I) and collagen3a1 (Col3a1) with or without TGF-b1
( Figure 2H-J) .
Then, we inhibited miR-30c expression by transfecting the cells with miR-30c inhibitors. Based on the qRT-PCR data, miR-30c expression was successfully inhibited in CFs ( Figure 3A) . MiR-30c
inhibitor increased CF proliferation with or without TGF-b1 compared with that in negative control group at 24, 48 and 72 hours via CCK-8 assay ( Figure 3B ). In addition, the a-SMA and vimentin levels were significantly increased in the miR-30c inhibitor + TGF-b1 group at 72 hours ( Figure 3C -E). MiR-30c inhibitor promotes CF migration ( Figure 3F , G). Contrary to the effects of miR-30c overexpression, inhibition of miR-30c increased the expression levels of Col I and Col3a1 ( Figure 3H-J) . Collectively, these data indicated that overexpression of miR-30c attenuates CF proliferation, differentiation and migration and collagen synthesis.
| miR-30c targets TGFbRII
According to the above results, we verified that miR-30c was involved in CF proliferation, differentiation and migration. Further, we wondered about the potential relationship between miR-30c and TGFbRII. Figure 4A shows the proposed microRNA binding site in 3 0 UTR of TGFbRII gene as well as mutant 3 0 UTR that was generated in this study. The luciferase activity was significantly decreased in pGL3-TGFbRII-WT + miR-30c group compared with that in pGL3-TGFbRII-mu + miR-30c group ( Figure 4B ). For further verification, we confirmed that up-and down-regulation of miR-30c in CFs could decrease and increase the mRNA and protein levels of TGFbRII after transfection with a miR-30c mimic or a miR-30c inhibitor in the absence or presence of TGF-b1 ( Figure 4C-H) . These outcomes verified that miR-30c could target TGFbRII.
| miR-30c prevents AAC-induced atrial fibrosis
To further determine whether miR-30c indeed plays a vital role in alleviating atrial fibrosis induced by AAC, we next used a heartspecific AAV9 via IVC injection to achieve overexpression of miR30c in left atrium. We confirmed that miR-30c expression was efficiently increased in the left atrium of rats in the AAC + miR-30c group via qRT-PCR ( Figure 5A ). In addition, the mRNA and protein expressions of TGFbRII were decreased in the AAC + miR-30c group TGFbRII. 43 Expression of miR-29 was decreased in the left atrium of dogs with heart failure, which develop an AF-maintaining fibrotic substrate. 7, 44 In contrast, miR-21 has been found to promote atrial fibrosis and fibrillation onset and can nearly abolish the duration of AF. 45, 46 During cardiac fibrosis, CFs underwent phenotypic transition to myofibroblasts marked by increased a-SMA, which is a reliable and classic marker for the myofibroblast. [33] [34] [35] In addition to the enhancement of contractility, myofibroblasts characteristically demonstrate increased migratory activity. 64 CF proliferation, migration and differentiation are important factors in cardiac fibrosis. MiR-30c has been reported to be involved in many cellular functions that lead to fibrosis, including cell proliferation, migration and differentiation. 54, 65 Our study indicated that miR-30c was regulated by TGF-b1. Therefore, in our study, we primarily focused on the effects of miR-30c on CF proliferation, migration and differentiation to determine the potential mechanism involved in atrial fibrosis.
Consistent with these reports, the present study confirmed that miR-30c inhibits the transformation of CFs into myofibroblasts induced by TGF-b1 by decreasing the expression of a-SMA and vimentin, whereas miR-30c inhibition promoted the expressions of a-SMA and vimentin. In addition, miR-30c mimic inhibited the differentiation of CFs as evidenced by a decrease in a-SMA staining (Fig- ure S1a). MiR-30c inhibitor promoted CF differentiation by increasing in a-SMA staining ( Figure S1b ). To the best of our knowledge, this is the first report that miR-30c exerts its cardio-protective properties by blocking fibroblast differentiation to myofibroblast.
Our data also revealed that miR-30c overexpression decreased cell proliferation and migration. Collectively, miR-30c reduced CF migration, preventing the accumulation of myofibroblasts and protecting against the fibrotic process. Aberrant fibroblast proliferation and their transformation to myofibroblasts, as well as migration, are hallmarks of cardiac fibrosis, which is characterized by excessive ECM deposition and leads to distorted organ architecture and function. 66, 67 Notably, miR-30c up-regulation was inversely correlated with the decreased expression levels of Col I and Col3a1 in cells treated with TGF-b1. ECM metabolic imbalance is involved in various cardiovascular diseases such as myocardial infarction, heart failure and AF. [68] [69] [70] Moreover, miR-30c overexpression decreased the ECM-regulated gene expression levels of Col I and Col3a1 in CFs, whereas MiR-30c inhibition promoted these processes.
TGFbRII is a transmembrane receptor necessary for TGF-b1 signal transduction activation. TGF-b1 is involved in the processes of pulmonary fibrosis and liver fibrosis. 24, 52 A previous study demonstrated that constitutive expression of dominant-negative TGFbRII in the posterior left atrium resulted in a significant decrease in atrial fibrosis via inhibition of the TGF signalling pathway and attenuated fibrosis-induced changes in atrial conduction and restitution to decrease AF. 27 The increased level of TGFbRII in the TGF-b1 group showed that TGFbRII may participate in TGF-b1-induced fibrosis.
Luciferase reporter assays confirmed that miR-30c led to a reduction in luciferase activity in TGFbRII 3 0 UTR-WT group, but had no effect when miR-30c binding site in TGFbRII 3 0 UTR was mutated, implying
TGFbRII is a target gene of miR-30c. The protein levels of TGFbRII were negatively correlated with miR-30c expression in AAC model and in the cellular model of fibrosis induced by TGF-b1. Overexpression of miR-30c decreased the level of TGFbRII, whereas miR-30c inhibition increased the level of TGFbRII. Therefore, TGFbRII, which is necessary for TGF-b1 signal transduction, may represent the point at which miR-30c inhibits the pro-fibrotic effects of TGF-b1.
The protective effects of miR-30c overexpression against atrial fibrosis were confirmed by overexpressing miR-30c via AAV9 in vivo.
In our vivo study, miR-30c overexpression markedly reduced atrial fibrosis compared with that in AAC group. We have determined for the first time that miR-30c overexpression might significantly reduce atrial fibrosis by targeting TGFbRII expression. Although several evidences here strongly support the functional role of miR-30c in regulating atrial fibrosis, more rigorous approaches are required to support this contention. This may include intra-myocardial rather than systemic delivery with a CF-specific promoter or using a miR-30c transgenic mouse model created using the CF-specific promoter.
Collectively, miR-30c may function by repressing TGFbRII expression, resulting in decreasing CF proliferation, differentiation, collagen synthesis and migration ( Figure 6 ).
Unfortunately, this study was performed in a model of atrial fibrosis, which does not induce AF by burst pacing ( Figure S2c ). Previous study reported that P wave duration (PWD) was useful in identifying patients at a risk for paroxysmal AF and was significantly correlated with the atrial electromechanical delay. 71 PR interval is an amalgamated measure of atrial and atrioventricular nodal conduction. PR interval prolongation increases AF risk and all-cause mortality. 72, 73 In F I G U R E 2 MiR-30c exhibited an anti-fibrotic effect on CFs. (A) CFs were transfected with a miR-30c mimic or miR-30c negative control (NC) for 72 hours. NC was used as a mimic negative control. The level of miR-30c was increased in CFs transfected with miR-30c mimic by qRT-PCR. # P < .05 compared with NC group. (B) After transfecting with a miR-30c mimic or NC, the CFs were stimulated with TGF-b1 (5 ng/mL) for 24, 48 or 72 hours. Overexpression of miR-30c inhibited CF proliferation performed with a CCK8-Kit assay. # P < .05, ## P < .01 compared with NC group; *P < .05 compared with NC + TGF-b1 group. (C-E) qRT-PCR, western blot and quantification analysis of levels of a-SMA and vimentin in CFs transfected with the miR-30c mimic or negative control in the presence or absence of TGF-b1 (5 ng/mL). # P < .05 compared with NC group; *P < .05, **P < .01 compared with NC + TGF-b1 group. (F) Representative photomicrographs of the migrating cells after transfection and staining by crystal violet (Scale bar, 100 lm). (G) The effect of the miR-30c mimic on the migration of the cells was quantified.
# P < .05 compared with NC group; *P < .05 compared with NC + TGF-b1 group. (H-J) The mRNA and protein levels of Col I and Col3a1 in CFs transfected with the miR-30c mimic were decreased in the presence or absence of TGF-b1 (5 ng/mL) via qRT-PCR, representative western blot and quantitative analysis for 72 hours.
# P < .05 compared with NC group; *P < .05 and **P < .01 compared with NC + TGF-b1 group. All experiments were repeated 3 times, and all data were presented as the mean AE SEM (n = 3, each)
XU ET AL. In conclusion, we suggest that TGF-b1 produces both profibrotic and anti-fibrotic signals and exogenous miR-30c administration decreases atrial fibrosis by counteracting the pro-fibrotic stimuli elicited by TGF-b1. Our data demonstrate that overexpression of miR-30c decreases left atrial fibrosis by inhibiting CF F I G U R E 3 The miR-30c inhibitor reversed the anti-fibrotic effects on CFs. (A) CFs were transfected with a miR-30c inhibitor or miR-30c inhibitor negative control (NC) for 72 hours. The level of miR-30c was decreased in CFs transfected with miR-30c inhibitor by qRT-PCR. NC was used as an inhibitor negative control. # P < .05 compared with NC group. (B) After transfecting with a miR-30c inhibitor or NC, the CFs were stimulated with TGF-b1 (5 ng/mL) for 24, 48 or 72 hours. A miR-30c inhibitor promoted CF proliferation evaluating by a CCK8-Kit assay. # P < .05, ## P < .01, compared with NC group; *P < .05, **P < .01, compared with NC + TGF-b1 group. (C-E) The levels of a-SMA and vimentin were increased in CFs transfected with the miR-30c inhibitor in the presence or absence of TGF-b1 (5 ng/mL) via qRT-PCR, western blot and quantification analysis. # P < .05 compared with NC group; *P < .05, **P < .01, compared with NC + TGF-b1 group. (F) Representative photomicrographs of the migrating cell after transfection and staining by crystal violet (Scale bar, 100 lm). (G) The effect of the miR-30c inhibitor on the migration of the cells was quantified. ## P < .01, compared with NC group; **P < .01 compared with NC + TGF-b1 group. (H-J)
qRT-PCR, representative western blot and quantitative analysis of the mRNA and protein levels of Col I and Col3a1 in CFs transfected with the miR-30c inhibitor or NC in the presence or absence of TGF-b1 (5 ng/mL) for 72 hours. A miR-30c inhibitor increased the levels of Col I and Col3a1. *P < .05, **P < .01, compared with NC + TGF-b1 group; # P < .05, ## P < .05, compared with NC group. All experiments were repeated 3 times, and all data were presented as the mean AE SEM (n = 3, each)
F I G U R E 4 MiR-30c targets TGFbRII. (A) Diagram of miR-30c binding site in TGFbRII 3 0 UTR. TGFbRII 3 0 UTR mutant was constructed to evaluate miR-30c binding. (B) After 293T cell cotransfection, luciferase activity was measured using a Dual Luciferase Report Assay Kit. The luciferase activity was significantly decreased in TGFbRII-WT + miR-30c group compared with that in TGFbRII-WT + miR-30c NC and TGFbRII-mu + miR-30c. ### P < .001, compared with pGL3-TGFbRII-WT + NC group. && P < .01, compared with pGL3-TGFbRII-mu + miR-30c group. (C-E) qRT-PCR and western blot analyses of CFs transfected with the miR-30c mimic or negative control for 72 hours in the absence or presence of TGF-b1. The miR-30c mimic decreased the mRNA and protein levels of TGFbRII. # P < .05, ## P < .05 compared with NC group; **P < .01, ***P < .01, compared with NC + TGF-b1 group. (F-H) The level of TGFbRII was increased after transfection with a miR-30c inhibitor as measured by qRT-PCR and western blot. # P < .05 compared with NC group; *P < .05 compared with NC+TGF-b1 group. All experiments were repeated 3 times, and all data were presented as the mean AE SEM (n = 3, each) proliferation, differentiation, migration and collagen production by targeting TGFbRII for the first time. Our study indicates that the application of exogenous miR-30c may be an attractive treatment strategy for atrial fibrosis and requires a further investigation in the future.
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